|1.||Ernst, Robert K: 15 articles (02/2014 - 01/2003)|
|2.||Jeannin, Jean-François: 11 articles (11/2014 - 03/2004)|
|3.||Miller, Samuel I: 11 articles (02/2014 - 01/2003)|
|4.||Hajjar, Adeline M: 6 articles (05/2015 - 01/2003)|
|5.||Trent, M Stephen: 6 articles (01/2015 - 02/2004)|
|6.||Paul, Catherine: 6 articles (11/2014 - 01/2009)|
|7.||Moskowitz, Samuel M: 6 articles (01/2014 - 01/2003)|
|8.||Bettaieb, Ali: 5 articles (11/2014 - 01/2009)|
|9.||Carlson, Russell W: 5 articles (06/2014 - 11/2002)|
|10.||Bishop, Russell E: 5 articles (02/2014 - 10/2009)|
12/01/1974 - "Protection against gram-negative infections with antiserum to lipid A from Salmonella minnesota R595."
01/01/2013 - "In this work, encompassing in vitro studies and in vivo studies of animal and human models of experimental genital tract infection, we document the importance of lipid A's structure, mediated by a single bacterial enzyme, LptA, in enhancing the fitness of Neisseria gonorrhoeae. "
02/17/2010 - "In this study we describe the use of a lipid-based delivery system/adjuvant, Lipid C, for oral immunization to protect mice against genital tract chlamydial infection. "
07/01/2008 - "This study analysed the effect of priming the innate immune system using synthetic lipid A mimetics in a Yersinia pestis murine pulmonary infection model. "
10/01/2015 - "The recombinant particles have recruited a lipid moiety to stabilize the native antigenic state that is different from the one used in a natural virus infection. "
01/01/2010 - "Substantive progress toward delineating the mechanisms involved in innate and adaptive tumor immunity has improved the prospects for crafting efficacious treatments LPS and their active component lipid A, have been used in tumor therapy since the 19th century.Studies"
01/01/2013 - "Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors."
01/01/2010 - " several lipid A species, including LPS and synthetic analogs, have been developed and tested as monotherapeutics for the treatment of cancer,1-8 only 3-O-desacyl-4'-monophosphoryl lipid A (MPL) has been evaluated as a cancer vaccine adjuvant in published human clinical trials. "
07/01/1961 - "Studies on the anti-tumor effect of the bacterial lipid component, lipid A. "
09/01/2015 - "Tumor biopsy proved a lipid-poor AML. "
|3.||Septic Shock (Toxic Shock Syndrome)
11/01/1996 - "It has recently been shown that inactive disaccharidic analogs of lipid A, an essential structure of lipopolysaccharide (LPS), may act as LPS antagonists which would be effective against septic shock induced by gram-negative bacteria endotoxin. "
07/01/1994 - "Protective effects of a monoclonal antibody against lipid A in endotoxic shock."
01/01/2013 - "The glycolipid lipid A is known to possess the minimal chemical structure for LPSs endotoxic activity, able to cause septic shock. "
06/01/2010 - "A fluorescence dye displacement assay shows strong affinities of the nanoparticles for lipid A, the glycolipid component of LPS responsible for septic shock. "
02/26/2009 - "We report the synthesis of these compounds, their in vitro activity as lipid A antagonists on HEK cells, and the capacity to inhibit LPS-induced septic shock in vivo. "
10/01/2009 - "Attention should be drawn to probucol, a lipid-lowering agent with potent antioxidant properties, which provides complete protection against Dox-induced cardiomyopathy in rats without interfering with the antitumor properties of Dox in an experimental setting. "
01/01/1995 - "In an earlier study, concurrent treatment with probucol (PROB), a lipid-lowering drug with strong antioxidant properties, was shown to offer only partial protection against ADR cardiomyopathy. "
06/01/1999 - "Probucol, a lipid-lowering drug, has been shown to offer protection against adriamycin-induced cardiomyopathy. "
06/01/1994 - "Since free radicals and lipid peroxidation are suggested to be involved in ADR cardiomyopathy, we examined the beneficial effects of probucol, a lipid-lowering drug with strong antioxidant properties. "
04/01/1995 - "Recently, it has been discovered that probucol, a lipid lowering agent and potent antioxidant, provides complete protection against adriamycin-induced cardiomyopathy in rats without interfering with the anti-tumor properties of this antibiotic. "
05/01/1995 - "We conclude that athletes have a lipid profile that may be protective against the development of atherosclerosis."
02/01/2008 - "Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the multi-ethnic study of atherosclerosis (MESA)."
09/15/2015 - "Atherosclerosis is a lipid-driven chronic inflammatory disorder. "
09/01/2015 - "Atherosclerosis is an inflammatory disease as well as a lipid disorder. "
06/16/2015 - "Atherosclerosis is a lipid-storage disease of arteries that is exacerbated by chronic inflammatory processes. "
|2.||Amphotericin B (Amphotericin)
|4.||SDZ MRL 953
|2.||Transplantation (Transplant Recipients)